# PCOS Gets a New Name to Better Reflect the Condition
The medical community has renamed polycystic ovary syndrome (PCOS) to polycystic metabolic syndrome (PMOS). The change aims to shift focus away from ovarian cysts, which are not present in all patients with the condition, toward the broader metabolic dysfunction that defines the disorder.
PCOS affects roughly one in ten women of reproductive age, causing irregular periods, fertility challenges, and increased risk for type 2 diabetes and heart disease. The old name misled both patients and doctors by emphasizing cysts visible on ultrasound, when the real problem lies in hormonal and metabolic imbalances. Many people with PCOS never develop cysts at all.
Doctors argue the new terminology will improve diagnosis rates and treatment outcomes. Under current naming conventions, some patients go undiagnosed because they lack visible cysts, even when they display classic PCOS symptoms like elevated androgens, insulin resistance, and irregular ovulation. The rename reflects what researchers have known for years: PCOS is fundamentally a metabolic disorder.
The condition involves insulin resistance in up to 70 percent of patients, driving excess androgen production and reproductive dysfunction. This metabolic component creates downstream risks for cardiovascular disease and diabetes that many patients never learn about. Better naming conventions help clinicians recognize these connections and treat the whole-body effects.
The shift also acknowledges that PCOS affects people assigned male at birth and those outside reproductive years, populations often overlooked under the old disease label. Renaming PCOS to PMOS positions practitioners to screen more broadly and catch cases earlier.
Patient advocacy groups support the change, noting that many people with PCOS felt their condition was trivialized or misunderstood because of emphasis on "cysts." A more accurate name reduces delays in diagnosis and